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Protein-engineering methods have been exploited to produce a surrogate
system for the extracellular neurotransmitter-binding site of a heteromeric
human ligand-gated ion channel, the glycine receptor. This approach
circumvents two major issues: the inherent experimental difficulties in working
with a membrane-bound ion channel and the complication that a heteromeric
assembly is necessary to create a key, physiologically relevant binding site.
Residues that form the orthosteric site in a highly stable ortholog, acetylcholine-
binding protein, were selected for substitution. Recombinant proteins were
prepared and characterized in stepwise fashion exploiting a range of biophysical
techniques, including X-ray crystallography, married to the use of selected
chemical probes. The decision making and development of the surrogate, which
is termed a glycine-binding protein, are described, and comparisons are
provided with wild-type and homomeric systems that establish features of
molecular recognition in the binding site and the confidence that the system is
suited for use in early-stage drug discovery targeting a heteromeric / glycine
receptor.
1. Introduction
Pentameric ligand-gated ion channels (pLGICs) are important
neurotransmitter receptors in the human central nervous
system (CNS). The pLGIC family includes the -aminobutyric
type A receptors (GABAARs), nicotinic acetylcholine recep-
tors (nAChRs), the 5-hydroxytryptamine type 3 receptor
(5-HT3R) and, of particular interest to us, glycine receptors
(GlyRs). The proportionate activation of these receptors
ensures a balance between neuronal excitation and inhibition
(Corringer et al., 2012; Lemoine et al., 2012; Thompson et al.,
2010), and mutations that perturb the balance are associated
with neurological and psychiatric disorders (Helbig et al., 2008;
Shiang et al., 1993). The pharmacological relevance of pLGICs
is well recognized, with members being targeted by anesthetics
or drugs to treat anxiety as examples (Lemoine et al., 2012;
Olsen, 2018). The successful use of relatively few drugs against
the large pLGIC family suggests future opportunities for drug
discovery if an improved understanding of specific structure–
activity relationships, appropriate chemical tools and tech-
niques were available. However, there are inherent difficulties
in targeting complex, multi-subunit membrane-bound ion
channels for drug discovery. The presence of detergents can
complicate compound screens, and multiple ligand-binding
sites that vary depending on the conformational state of the
ion channel are also problematic. To this we add the very
significant complication that the overwhelming majority of
human pLGICs of physiological and pharmacological rele-
vance are heteromeric, with distinct subunit combinations that
display unique biophysical and pharmacological profiles.
These assemblies are unevenly distributed throughout the
CNS and its periphery, and the heterogeneity provides an
opportunity for the development of ligands with receptor-
subtype specificity (Dutertre et al., 2012; Shan et al., 2012;
Webb & Lynch, 2007). In large part, owing to difficulties in
the recombinant protein production of heteromeric samples,
structural studies are largely restricted to homomeric pLGICs,
with a limited capacity to characterize the details of selectivity
that can guide the development of selective chemical probes
necessary to support fundamental studies or drug discovery.
There have been modeling exercises (Bergmann et al., 2013;
Richter et al., 2012) and very recently highly significant
progress with studies of the heteromeric human 42 nAChR
(Morales-Perez et al., 2016; Walsh et al., 2018) and 
GABAA receptors (Laverty et al., 2019; Masiulis et al., 2019;
Phulera et al., 2018; Zhu et al., 2018).
Our interest is the GlyR subtype, a particularly appealing
target for the development of novel muscle relaxants and the
treatment of neuropathic pain (Burgos et al., 2016; Imlach,
2017; Lynch, 2009; Lynch et al., 2017). The prevalent forms of
human GlyR are 1 heteropentamers with 2:3 or 3:2
stoichiometry (Durisic et al., 2012; Grudzinska et al., 2005;
Yang et al., 2012). Several lines of evidence support the
existence of mammalian glycine receptors with the 21:3
stoichiometry. Firstly, mutagenesis
experiments implicate residues in the 
subunit in binding glycine to 1
receptors expressed in Xenopus oocytes
(Grudzinska et al., 2005). Secondly,
experiments with concatenated 1-
tandem constructs demonstrated that
functional receptors were only
expressed with the additional inclusion
of the  subunit, but not the 1 subunit,
implicating 21:3. Thirdly, atomic
force microscopy with epitope-tagged
1 and  subunits expressed in HEK293
cells indicated a 21:3 stoichiometry
(Yang et al., 2012). Mutations affecting
key residues in the orthosteric agonist
site at the 1()/(+) interface affect
the potency of both activation by
glycine and inhibition by strychnine
(Grudzinska et al., 2005). We therefore
set out to generate a high-fidelity
surrogate of this 1()/(+) orthosteric
binding site using the 21:3 stoich-
iometry [Fig. 1(a)] by exploiting
protein-engineering methods and the
thermal stability of acetylcholine-
binding protein fromAplysia californica
(AcAChBP). Acetylcholine-binding
protein is a highly conserved ortholog of
the pLGIC extracellular ligand-binding domain (ECD) with
properties similar to nAChR (Lemoine et al., 2012; Rucktooa
et al., 2012; Sauguet et al., 2015; Shahsavar et al., 2016; Sixma &
Smit, 2003). Studies on AcAChBP and the Lymnaea stagnalis
protein (LsAChBP) have defined the selective recognition of
ligands and provided surrogates for the excitatory nAChR and
5-HT3R ECDs (Kesters et al., 2013; Price et al., 2016). We
outline comparative informatics that guided decision making
and the characterization of the resulting proteins as we, in
stepwise fashion, converted AcAChBP to a glycine-binding
protein (GBP) displaying an orthosteric site with the struc-
tural features of heteromeric human 1()/(+) GlyR.
Crystallographic and cryo-EM structures of homomeric
human GlyR-3 (Huang et al., 2015; Huang, Chen et al., 2017;
Huang, Shaffer et al., 2017) and zebrafish GlyR-1 (Du et al.,
2015) provide templates that validate our approach.
2. Materials and methods
2.1. Site-directed mutagenesis and protein production
The amino-acid sequences corresponding to AcAChBP
(Q8WSF8) and humanGlyR-1 (P23415) and GlyR- (P48167)
were retrieved from UniProt (http://www.uniprot.org/). Our
numbering scheme correlates with the full-length sequences in
these entries. A series of models were prepared using Phyre
(Kelley et al., 2015). Sequences were aligned with Clustal
Omega (Sievers & Higgins, 2014), and the structure of
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Figure 1
A schematic of a heteropentameric GlyR. The stoichiometry is (1)2()3, with the 1 subunit in red
and the  subunit in cyan. Plus and minus symbols indicate the positions of the principal and
complementary sides of the binding site, respectively. In this arrangement there are three types of
binding site: two 1(+)/(), two 1()/(+) and one (+)/(). (b) Comparison of the loop
segments that create the orthosteric ligand-binding sites inAcAChBP, human GlyR-1 and GlyR-.
The residues colored red indicate where amino-acid substitutions have been carried out to create
GBP. The four residues colored blue contribute to the binding site but have not been changed owing
to structural conservation.
AcAChBP (for example PDB entry 2xys; Brams et al., 2011)
and homology models were inspected, and mutations were
modeled in Coot (Emsley & Cowtan, 2004) to inform the
design of substitutions. A stepwise approach was adopted,
leading to assessments of which substitutions were important
and tolerated, i.e. produced soluble, stable protein that was
able to bind known ligands, taking into consideration ligand
selectivity compared with the wild type (WT). The DNA
encoding AcAChBP, together with several other constructs,
was purchased from GenScript. Site-directed mutagenesis was
carried out and altered genes were ligated into the pFastBac
system for secretion using the baculovirus/Sf9 system. Protein
preparation followed published methods (see, for example,
Hansen et al., 2004) and included the use of affinity and size-
exclusion chromatography.
2.2. Thermostability and ligand binding
Fluorescence-based screening by differential scanning
fluorimetry (DSF; see, for example, Eadsforth et al., 2012) was
used to determine the melting temperature (Tm) values. An
Mx3005P RT PCR system (Stratagene) was used to monitor
protein unfolding by the increase in fluorescence of SYPRO
Orange dye (Invitrogen). Assays were carried out in 40 ml
volumes with proteins at around 10 mM in 50 mM Tris–HCl,
250 mM NaCl pH 7.5 in 96-well RT PCR plates (ABgene). To
investigate the influence of the chemical probe strychnine, 1 ml
of strychnine dissolved in DMSO or buffer and then diluted
with buffer was incubated with the protein solutions for 5 min
prior to 71 cycles of 1C temperature increments starting at
25C. After each 1C increase the sample was excited at
492 nm and fluorescence emission was recorded at 610 nm.
The melting temperatures were plotted against a reference
control sample of DMSO only. The strychnine concentration
varied between 0.1 and 65 mM, with a requirement to limit the
concentration of DMSO in the final mixture to <2.5%. Data
are presented in Supplementary Table S1.
2.3. Isothermal titration calorimetry (ITC)
The interaction of strychnine with AcAChBP and GBP was
investigated using ITC. Measurements were carried out with a
MicroCal PEAQ-ITC (Malvern Panalytical) at 25C. The
protein solutions (10 mM AcAChBP, 40 mM GBP) were
prepared by dialysis against buffer (50 mM Tris–HCl pH 7.5,
250 mM NaCl) at 4C overnight. Strychnine solutions
(concentrations of 100 and 500 mM) were prepared in the
same buffer. For the experiments, the initial injection of one
0.4 ml aliquot was followed by 17  2 ml injections at 3 min
intervals. In each case the injection needle acted as a paddle,
stirring the cell contents at 750 rev min1, and the reference
was set at 10 mcal s1. Data were analyzed using the software
supplied by the manufacturer to calculateKd,H,TS,G
and N, which were derived from a one-binding-site model.
Control measurements, buffer into buffer, strychnine into
buffer and buffer into protein solutions, were used to deter-
mine an appropriate offset adjustment. Examples of the data,
averaged parameters and standard errors derived from three
titrations are presented in Supplementary Fig. S1.
2.4. Tryptophan fluorescence-quenching assay
Measurements were recorded using a PerkinElmer LS-55
spectrophotometer with the detector sensitivity set to 750 V.
Stock solutions of 10 mg ml1 GBP and AcAChBP were
prepared, along with two strychnine stock solutions of 100 mM
and 1 mM in the same buffer as used for the ITC experiments.
The protein samples (2 ml) were excited at a wavelength of
280 nm, and emission was recorded between 300 and 400 nm.
For GBP, aliquots of 20 ml of the 1 mM strychnine stock were
used, followed by mixing. For AChBP, additions of 2 ml of the
100 mM strychnine stock were made, followed by mixing.
Experiments were carried out in triplicate and the percentage
change in fluorescence was calculated. Data were analyzed
usingMicrosoft Excel andGraphPad Prism 7. Examples of the
data, parameters and standard errors derived from three
titrations are presented in Supplementary Fig. S2.
2.5. Crystallographic analyses
Each protein sample (4 mg ml1 in 50 mM Tris–HCl pH 7.5,
250 mM NaCl) was incubated with the appropriate ligand for
1 h before setting up crystallization trials using sitting-drop
vapor diffusion with standard sparse-matrix screens. Initial
conditions were identified and then optimized for each sample
(Supplementary Table S2). Ultimately, this led to six distinct
crystal forms. Crystals were harvested using a nylon loop,
cryoprotected with reservoir solution adjusted to contain 30%
ethane-1,2-diol or 30% glycerol and then flash-frozen in liquid
N2. Diffraction data were recorded in-house, using beamline
I04-1 at Diamond Light Source or beamline ID23-1 at the
European Synchrotron Radiation Facility. Images were
indexed and integrated using XDS (Kabsch, 2010). The data
were scaled using AIMLESS (Evans & Murshudov, 2013)
from the CCP4 suite (Winn et al., 2011) and the structures
were solved by molecular replacement with Phaser (McCoy et
al., 2007). The initial model for molecular-replacement
calculations was the wild-type structure (PDB entry 2xys).
Multiple rounds of automated restrained refinement in
REFMAC5 (Murshudov et al., 2011) combined with electron-
density and difference density map inspection and inter-
pretation using Coot (Emsley & Cowtan, 2004) were carried
out. Asn91 is glycosylated and N-acetyl-d-glucosamine was
modeled onto several subunits. Whilst inspecting the different
maps it was clear that additional ligands present in the crys-
tallization mixture were ordered in the structures. These were
assigned and refined satisfactorily as chloride, citrate, ethane-
1,2-diol, isopropyl alcohol or phosphate. Water molecules and
side-chain conformers were included in the models as appro-
priate. The asymmetric units of the different crystal forms
contained either five, ten or 15 subunits, and strict noncrys-
tallographic symmetry restraints were applied during most of
the refinement and were relaxed towards the end of the
process. Dictionaries of ligand restraints were assembled using
grade (Smart et al., 2014). Model geometry was assessed with
research papers
IUCrJ (2019). 6 Alice Dawson et al.  Surrogate heteromeric / glycine receptor orthosteric site 3 of 10
MolProbity (Chen et al., 2010) and the PDB validation tools.
Figures were generated using PyMOL (Schro¨dinger). Further
details, including relevant statistics, are presented in Supple-
mentary Table S3 and Fig. S3.
3. Results and discussion
3.1. Comparison of AcAChBP and GlyR sequences to inform
surrogate design
The alignment of the amino-acid sequences of AcAChBP,
human GlyR-1 and human GlyR- [Fig. 1(b)], and homology
modeling together with published mutagenesis data (see, for
example, Grudzinska et al., 2005; Pless, Hanek et al., 2011;
Pless, Leung et al., 2011; Yu et al., 2014) on the effects of
specific substitutions were used to guide the conversion of the
orthosteric site of AcAChBP to that of a human GlyR-1()/
(+) heteromer. The orthosteric site is constructed at the
subunit–subunit interface by seven loop segments. Three of
these loops (labeled A–C) form the (+) or principal side of the
site and four (labeled D–G) form the () or complementary
side [Fig. 1(b)]. Loop F was judged to be sufficiently distant
from the orthosteric binding site to be ignored. Residues with
side chains directed into the orthosteric site were marked for
attention (Fig. 2, Table 1). In stepwise fashion, we generated
baculovirus expression systems encoding genes for WT and
altered versions of AcAChBP, purified and characterized the
recombinant proteins to understand the consequences of
alterations in and around the orthosteric site. DSF allowed us
research papers
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Figure 2
Schematic to describe the construction of and key residues in the
orthosteric binding site of AcAChBP and the corresponding amino acids
in the human GlyR-1()/(+) heteromeric site. Substitutions in red
convert AcAChBP into GBP.
Table 1
Contributions of key residues in the orthosteric site of AcAChBP and the human GlyR-1()/(+) heteromeric site.
Residues in bold were substituted with the human equivalents to create glycine-binding protein (GBP).
AcAChBP GlyR-(+)
Residue Loop Role Residue Comment
Tyr110 A Aromatic lining of the site, with hydroxyl
contribution
Ala146 Reduction in size, makes space for Glu202
Gly162 B Adjacent to Tyr110 Glu202 Increase in size and introduces negative charge
Ser163 B Hydroxyl forms a hydrogen bond to the Tyr166
amide to hold Trp164 and Val165 in place
Ser203 Strictly conserved
Trp164 B Aromatic contribution to site, inter-subunit
hydrogen bond to Ile135 carbonyl
Phe204 Conserved aromatic with slight reduction in
bulk, no hydrogen bond
Val165 B Hydrophobic contribution Gly205 Reduction in size
Tyr205, Tyr212 C Tyrosine pair contributes aromatic lining and
hydroxyls to site
Tyr247, Tyr253 Strictly conserved
Ser206, Cys207,
Cys208, Pro209
C Disulfide contributes hydrophobic lining to site
and restrains the loop conformation
Lys248, Gly249,
Thr250, Gly251
Changes likely to give more conformational
freedom to loop C
AcAChBP GlyR-1()
Residue Loop Role Residue Comment
Tyr72 D Aromatic contribution Phe91 Conserved
Gln74 D Abuts Ile135, Met133 Arg93 Introduction of bulk and positive charge
Ile123, Ala124,
Val125
E Hydrophobic contributions from Val125 and
Ala124 C; Ile123 carbonyl directed into site
Leu145, Leu146,
Arg147
Conserved Ile/Leu but increase in size for
Leu146 and Arg147; aliphatic part of Arg147
side chain lines site
Met133 E Hydrophobic lining to site, inter-subunit van der
Waals interactions with loop C disulfide
Leu155 Conserved
Ile135 E Hydrophobic lining Ser157 Reduction in size allows space for Arg93,
addition of a polar group in site
Thr53 G Abuts Tyr72 Phe72 Increase in bulk and hydrophobicity to position
Phe91
Gln55 G Inter-subunit hydrogen bond to carbonyl serves
to place Tyr110 and van der Waals
interactions to position Tyr72 in site
Asn74 Conserved
to measure the changes in stability (Tm) as a consequence of
amino-acid substitutions and ligand binding (Supplementary
Table S1). Tryptophan fluorescence provided data relating to
binding affinity, and crystallographic analyses of eight ligand
complexes provided structural data (Supplementary Table S3,
Figs. S2 and S3). Three well characterized pLGIC modulators,
nicotine, tropisetron and strychnine, were used as chemical
probes to provide control data.
3.2. Characterization of variants I and II
The AcAChBP–nicotine complex crystal structure provided
a check of the orthosteric binding site and direct comparison
with the LsAChBP complex (Celie et al., 2004), and confirmed
that the binding sites and protein–ligand interactions are
highly conserved. The orthosteric site is a narrow hydrophobic
cavity dominated by five aromatic residues on one side, a
disulfide bond and four aliphatic residues on the other. Of 20
residues that contribute to this site (Table 1), 17 are conserved
between AcAChBP and LsAChBP, with only three differences
of note: Val125 in AcAChBP changes to arginine, Thr53 to
lysine and Gln55 to isoleucine. The Thr53/Gln55 combination
contributes to the positioning of Tyr72, which interacts directly
with ligands. In LsAChBP, the aliphatic parts of the lysine and
the isoleucine side chains help to position a tryptophan, which
occupies the place of Tyr72 in AcAChBP. In AcAChBP, the
side chain of Val125 contributes to a hydrophobic surface of
the orthosteric site and also serves to position the side chain of
Arg96, which participates in an inter-subunit salt bridge with
Glu170. In LsAChBP, the glutamate is conserved and the
equivalent residues to Arg96 and Val125 are serine and argi-
nine, respectively. The smaller serine side chain provides space
for the arginine to occupy the same position to also form a salt
bridge with the conserved glutamate, whilst the aliphatic
component of the arginine essentially mimics the contribu-
tions of Val125 to the binding site.
Variant I incorporated five changes: T53F, Q74R, Y110A,
I135S and W164F. The key observation from the structure of
the variant I strychnine complex concerned the Y110A,W164F
and I135S substitutions. Trp164 NE1 donates a hydrogen bond
to the carbonyl of Ile135, thus linking two -strands from
different subunits. Removal of the stabilizing interaction is
likely to contribute to Tm of this variant (40C) compared
with the wild-type protein. We also note a biphasic melting
curve that may represent first dissociation of the pentamer
followed by unfolding of the subunit. The electron density of
the phenylalanine (Phe164) was poorly ordered, perhaps as
the reduction in the side-chain size of an adjacent residue
(Y110A) opened up one side of the binding site, allowing a
greater degree of conformational freedom. This variant
nevertheless retained the ability to bind strychnine, as
revealed in the complex crystal structure and by a Tm of
+20C. The structure also indicted that the Y110A substitution
created space to accommodate a G162E substitution (see
later). Thr108 abuts Trp164 on adjacent -strands in
AcAChBP, and we reasoned that Trp164 could be retained
since the residue equivalent to the adjacent Thr108 is Phe144
in human GlyR- and the six-membered ring of the indole
would replicate the Phe144/Phe204 combination in the human
system. The retention of tryptophan also preserved the ability
to exploit fluorescence measurements for binding studies.
Variant II therefore reverted back to Trp164, but with the
inclusion of a G162E substitution. The residues now changed
(Thr53, Gln74, Tyr110, Ile135 and Gly162) correspond to
Phe72, Arg93, Ala146, Ser157 and Glu202 in the human GlyR-
1()/(+) orthosteric site [Figs. 1(b) and 2]. The important
aromatic residues Tyr72 (Phe91), Trp164 (Phe204), Tyr205
(Tyr247) and Tyr212 (Tyr253) are well conserved in the two
systems [Figs. 1(b) and 2]. The Tm of 80
C for variant II is an
increase of 25C compared with variant I and is only 10C
lower compared with the WT protein. The incorporation of
the inter-strand hydrogen bond between Trp164 and Ile135 is
likely to support this recovery of thermal stability. Strychnine
binding to variant II resulted in a Tm of +5
C.
Crystal structures of variant II with HEPES, tropisetron and
strychnine revealed that the G162E substitution was accom-
modated with the structure essentially unperturbed compared
with variant I, although now incorporating two charged resi-
dues (Arg74 and Glu162) to polarize the binding site such that
the principal side is negatively charged and the complemen-
tary side is positive. The complex structure with HEPES
showed this crystallization buffer component binding in two
orientations in the orthosteric site in a similar fashion to that
reported for LsAChBP (Celie et al., 2004). The variant II
complex showed tropisetron [Fig. 3(a)] to be present in two of
the ten orthosteric sites in the asymmetric unit, with the other
sites being occupied by the cryoprotectant ethane-1,2-diol and
the N-terminal histidine tails of symmetry-related molecules.
Although the tropisetron occupies the same space, our inter-
pretation of the electron density is that this modulator of
GlyR (Yang et al., 2007) displays two poses [Supplementary
Figs. S3(c) and S3(d)]. One pose is similar to that observed in
the WT AcAChBP (Hibbs et al., 2009) complex, whilst the
other is rotated approximately 180 (Fig. 3). When bound to
the WT protein, the tropane-bridged piperidine binds in the
same position as the pyrrolidine moiety of nicotine, forming
van der Waals interactions with the side chains of Tyr72 from
one subunit and Tyr205, Tyr212 and Trp164 from the other
subunit. The quaternary amine N1 donates a hydrogen bond
to the carbonyl of Trp164 and the methyl substituent forms
van der Waals interactions with Tyr110. A solvent-mediated
hydrogen-bonding network links the tropisetron carbonyl to
the carbonyl of Val165 and Tyr212 hydroxyl group of one
subunit and the carbonyl groups of Ile106 and Met133 on the
partner subunit. The ether/carbonyl link between the tropane
and indole groups forms van der Waals contacts to the
Cys207–Cys208 disulfide part of loop C on the (+) side and the
side chain of Ile135 on the () side. The indole group is
positioned with van der Waals contacts to Cys207 on one side
and to the side chains of Tyr72, Gln74 and Met133 on another
subunit. The indole N10 forms a hydrogen bond to a water
molecule, which in turn interacts with Thr53 and Asp181 and
other solvent molecules that form a network of hydrogen
bonds in and around the binding site. The second pose is
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influenced by the Y110A and G162E substitutions, which
allow a solvent-bridged interaction between the glutamate and
tropisetron N1. van der Waals interactions between the
tropane and aromatic residues are maintained in both poses
with minor adjustments of side chains. The T53F substitution
and the placement of the aromatic group help to place the
arginine from the Q74R substitution to participate in a cation–
 stacking arrangement of the guanidinyl moiety and the
indole system, pushing tropisetron over towards the disulfide
linkage on loop C. A solvent-mediated link between Ser135
and Arg74 may also contribute to the placement of the
guanidinyl moiety. The indole N10 is directed out towards
bulk solvent, whilst the carbonyl group accepts a hydrogen
bond donated from the side chain of Tyr72.
Of note is the observation that tropisetron can adopt two
poses in the same binding site. It is not unusual to observe a
statistical disorder in which two orientations of a ligand are
present in the population of molecules in a crystal (see, for
example, Khalaf et al., 2014). The possibility exists that here
also tropisetron adopts more than one orientation in the
binding site, in effect a mixed population, but the electron-
density maps suggest a dominant pose in each of the two
binding sites that are occupied [Supplementary Figs. S3(c) and
S3(d)]. This observation matches well with previous work on
tropisetron and derivatives interacting with the 5-HT3R that
indicate that different binding orientations are possible
(Ruepp et al., 2017).
The Kd values for the binding of nicotine and tropisetron to
AcAChBP are 250 and 480 nM by monitoring intrinsic tryp-
tophan fluorescence quenching with stopped-flow spectro-
fluorimetry (Hansen et al., 2005). Comparable values were
obtained with our tryptophan fluorescence measurements:
245 (20) and 275 (15) nM. This validated assay was applied
to investigate how the substitutions might influence ligand
affinity. Neither variant I nor variant II appeared to be able to
bind nicotine. The combined Y110A and I135S substitutions
may open up the binding site such that nicotine can longer
bind in an optimal fashion. However, we were unable to co-
crystallize these variants with glycine, neither did the fluor-
escence assay register any glycine binding.
3.3. Variant III is a glycine-binding protein
Variants I and II presented structural features consistent
with site-directed mutagenesis and electrophysiological data
that suggest interacting roles for specific residues (see, for
example, Yu et al., 2014). However, our structures also
emphasized that accurately replicating the ()/(+) hetero-
meric site required changes to the (+) side loop C, where the
major differences between -form and -form sequences
occur (Figs. 1 and 2). Single-site substitutions were not obvious
and we judged it necessary to make a major change, with four
substitutions being incorporated (S206K, C207G, C208T and
P209G). These substitutions had the potential to release the
conformational restraint of the Cys207–Cys208 disulfide and,
with two glycine residues now included, to increase the
conformational mobility of the loop. Variant III was produced
in recombinant form and characterized.
The substitutions did not have an adverse effect on the
stability of the protein, with Tm values of 80 and 81
C noted
for variants II and III, respectively (Supplementary Table S1).
The binding of strychnine to variant III led to a small increase,
+3C, inTm, and when glycine was tested aTm of +2C was
observed. These changes are small and are unlikely to be
significant. Attempts to observe an association between
variant III and glycine using the fluorescence assay, ITC and
biolayer interferometry failed to show any binding. This may
be a consequence of testing a compound with such a low mass
(about 75 Da). However, variant III co-crystallized with
glycine and the ligand occupies four of the five orthosteric
binding sites in the asymmetric unit. With this proof of binding
we named variant III glycine-binding protein (GBP). The
molecular packing in the crystal lattice of the GBP–glycine
complex places a histidine from the affinity tag in the other
site. The structure of wild-type AcAChBP in complex with
strychnine, the archetypal GlyR antagonist, reported here as a
control (PDB entry 2xys; Brams et al., 2011) provided a
comparison for the GBP–strychnine complex, which we also
crystallized. During our study, crystal structures of homomeric
human GlyR-3 complexes with glycine (PDB entry 5tin) and
research papers
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Figure 3
Tropisetron adopts two poses in the orthosteric site of variant II. (a) The
chemical structure of tropisetron. (b) The interacting residues of variant
II are shown with C positions colored white for the principal side and
cyan for the complementary side, with one tropisetron pose (yellow C
positions). Two water molecules discussed in the text are depicted as blue
spheres; O and N positions are red and blue, respectively. Selected
hydrogen-bonding interactions are shown as blue dashed lines. The
second pose, which is common with that adopted in WT AcAChBP (PDB
entry 2wnc), is shown with black C atoms.
strychnine (PDB entry 5cfb) became available (Huang, Chen
et al., 2017; Huang, Shaffer et al., 2017), allowing direct
comparisons.
The orthosteric site in the GBP–glycine structure is highly
conserved with that of the WT GlyR homomer structures and
variants I and II, with the notable exception of loop C, which
now adopts a configuration that allows two tyrosine residues
(Tyr205 and Tyr212) to contribute to the binding site (Fig. 4).
One edge of the Tyr205 side chain helps to form one side of
the binding site, with the hydroxyl group placed to donate a
hydrogen bond to the carbonyl of Tyr166 (not shown), thereby
linking two segments, and to accept a hydrogen bond from the
glycine ligand. Tyr212 is aligned with Tyr205, creating a
-electron-rich region to interact with the glycine amino
group. Solvent-mediated interactions link the Tyr212 hydroxyl
with the carboxylate of Glu162 (not shown), which in turn
interacts with the glycine amino group. The glycine is tucked
between and participates in van der Waals interactions with
the edge of Tyr205 and the face of the Trp164 indole. The
glycine carboxylate is directed towards the Arg74 guanidinyl
moiety, but the distances (3.8 A˚) are too long to represent
direct hydrogen-bonding interactions and a solvent-mediated
association is noted.
In the structure of the homomeric GlyR-3 glycine complex
(Huang, Shaffer et al., 2017), the glycine carboxylate accepts
hydrogen bonds donated by the side chains of Arg65, Ser129
and Thr204, the latter on loop C. The amino group of the
ligand makes a solvent-mediated interaction with Glu157 and
a direct hydrogen bond to the carbonyl of Phe159. The glycine
participates in van der Waals interactions with the side chains
of Phe63 and Phe159, whilst the amino group occupies a
-electron-rich area between Phe159 and Phe207. A water
molecule bridges this amino group to the carbonyl of Ser158
and the carboxylate of Glu157 with three hydrogen bonds. The
major differences between the two structures and the key to
forming a heteromeric site reside in loop C, the part of the
binding site that distinguishes the - and -forms of the
receptor. In GlyR-3 the loop segment comprising residues
199–207 is in a closed conformation, whilst the equivalent
residues 202–211 in GBP form a more open structure.
However, in GBP the loop conformation places the side chains
of the tyrosine pair (205 and 212) directed into the binding
site, whereas in GlyR-3 only one tyrosine, Tyr202, is thus
positioned, forming a hydrogen bond with the conserved
acidic Glu157.
The structure of the GBP–strychnine complex displays a
well ordered ligand in three out of five binding sites per
asymmetric unit. In two sites the density is less clear, the
thermal parameters are elevated (Supplementary Table S3)
and different strychnine orientations are noted. A previously
published structure of the WT AcAChBP–strychnine complex
shows a single molecule occupying four of the five orthosteric
sites in the asymmetric unit and one site with two ligands
bound (Brams et al., 2011). In both of these structures the
molecular packing in the crystal lattice affects the conforma-
tion of loop C in one subunit and results in a more open
binding site, providing room for ligands to adopt different
orientations. We note also that this alkaloid displays a
propensity to dimerize or aggregate at high concentrations
(Reinscheid et al., 2016). Our structure of the WT AcAChBP–
strychnine complex displays a single well ordered strychnine
in all five binding sites per asymmetric unit and we confine our
comparison to this binding pose (Fig. 5).
The orientation and the position of the alkaloid in both WT
AcAChBP structures is very similar. There is a single direct
hydrogen bond between the alkaloid and the protein donated
by the protonated tertiary amine to the carbonyl of Trp164.
The pKa of strychnine is approximately 8.3 (Haynes, 2015),
hence the confidence that protonation has occurred. The
potential hydrogen-bond acceptors on strychnine, ether and
amide O atoms, are placed to interact with solvent and in so
doing then form bridges to the protein. Extensive van der
Waals interactions involving four tyrosine residues (110, 205,
212 and 72), Trp164, Met133, Ile135 and the Cys20–Cys208
disulfide are likely to explain the high affinity of strychnine for
this binding site, with a reported Ki of 38 nM (Brams et al.,
2011) and Kd of 15 nM (Hansen et al., 2004), the latter based
on a stopped-flow spectrofluorimetry assay. The use of ITC
and a radioligand saturation assay to characterize the inter-
action between strychnine and a recombinant homomeric
GlyR-1 system gave Kd values of 138 (55) and 52 (6) nM,
respectively (Wo¨hri et al., 2013). The application of ITC and
surface plasmon resonance methods with recombinant
homomeric GlyR-3 produced Kd values of 52 (2) and 43
(3) nM, respectively (Huang et al., 2015). For comparative
purposes we employed ITC to characterize the binding of
strychnine to WT AcAChBP and GBP (Supplementary Fig.
S1). The resulting Kd for the interaction with WT AcAChBP is
74.1 (22.6) nM and that with GBP is 28.8 (3.2) mM.
Corroboration of these data was sought using a fluorescence-
based assay, where Kd values of 155 (7) nM and 27
(0.5) mM were determined for WT AcAChBP and GBP,
respectively.
Strychnine is a promiscuous ligand that is active against
different receptors. Electrophysiological assays indicate that
the alkaloid, although the prototypical competitive antagonist
of GlyR, also displays the same activity against some nAChR
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Figure 4
Glycine in an orthosteric site of GBP. A similar color scheme as shown in
Fig. 3 is used, with glycine C positions in black.
subtypes, with IC50 values that range from 350 nM to around
40 mM (Albuquerque et al., 1998; Garcı´a-Colunga & Miledi,
1999; Jensen et al., 2006). The affinity of strychnine interacting
with AcAChBP is consistent with the activity that this ligand
displays against the orthologous binding sites presented by
nAChRs. The substitutions that were introduced to engineer a
glycine-binding site in GBP have however reduced the affinity
for strychnine significantly away from that of the wild-type
template as well as from that observed with recombinant
homomeric GlyR samples. The thermodynamic parameters
[Supplementary Fig. S1(e)] indicate that whilst the enthalpic
contribution to strychnine binding is similar for AcAChBP
and GBP, there is a significant penalty in the entropic contri-
bution that explains the reduced affinity of GBP for this
ligand. We speculate that this may be linked to a reduction in
thermal stability of GBP relative to the wild-type protein and/
or be influenced by the increased flexibility introduced into
loop C. The observation does have an important implication
for our use of the GBP surrogate, suggesting that care should
be applied when using this system with larger ligands that
might engage with residues distant from those involved
directly in neurotransmitter binding.
TheWTAcAChBP, GlyR-3 homomer and GBP complexes
display different orientations of strychnine in the binding site
that are directly linked to the substitutions that have been
incorporated to produce GBP (Fig. 5). An overlay of the
protein structures (data not shown) places the tertiary amines
within 2 A˚ of each other, but the ligands adopt different poses,
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Figure 5
Strychnine bound to GBP. (a) The chemical structure of the natural product. (b) The key residues and orientation of strychnine bound to GBP. A similar
color scheme as shown in Fig. 3 is used, with C positions of strychnine in black and C positions of acetate and ethanediol (EDO) in green. (c) The binding
of strychnine to the human GlyR-3 homomer from PDB entry 5cfb (Huang et al., 2015); the residue numbers in the PDB entry are retained. (d) For
comparative purposes the alignment of GBP [see Fig. 1(b)] with human GlyR-3 is shown using the numbering scheme of the PDB entry. Residues
shown in (c) are shown in gray for the principal side and in cyan for the complementary side.
essentially pivoting around this N atom. In the GBP–strych-
nine complex the tertiary amine is protonated and donates a
hydrogen bond to a highly ordered water that forms hydrogen
bonds to the carbonyl groups of Ser163 and Tyr166 and
contributes to a solvent network that burrows into the protein
fold (data not shown). The Y110A substitution removes the
possibility of van der Waals interactions between the aromatic
side chain and any ligand. The G162E change directs a polar
side chain into the bindng site and this forces the strychnine to
adopt a different orientation. On the other side of the binding
site, the Q74R substitution serves to place a polar group
further into the cleft. This would clash with the ligand orien-
tation noted in the wild-type AcAChBP complex and thus
works in concert with the presence of Ala110 and Glu162 to
position the ligand. The I135S and T53F changes allow Tyr72
to adopt a different rotamer conformation: in the former by
providing space and in the latter with stabilizing van der Waals
interactions. The position of Phe53 also serves to stabilize the
side-chain position of Arg74. The change in orientation of
strychnine results in the amide carbonyl O atom rotating by
about 90 and relocating by almost 8 A˚ directed towards
Met133 and with the indole system placed to interact with loop
C. Here also there are significant changes to the protein
structure. The side chain of Tyr205 adopts a different rotamer,
participates in van der Waals interactions with strychnine and
now occupies the space that is filled by the Cys207–Cys208
disulfide bond in WT AcAChBP, in essence forming a lid over
the binding site. Tyr212 also displays a different rotamer,
partially filling the space vacated by Tyr205, and this allows the
strychnine indole moiety to bind under loop C.
4. Conclusions
We sought to investigate the orthosteric binding site of the
heteromeric 1()/(+) form of human GlyR but circum-
venting the experimental difficulties of working with a multi-
subunit membrane-bound protein. Based on existing
sequence, structural and functional data, we considered which
amino acids of the homolog AcAChBP might be substituted,
allowing us to create a convenient surrogate system. In stages,
we modified AcAChBP and characterized variant proteins to
interrogate the binding site. Ultimately, the highly stable
AcAChBP framework has allowed us to introduce nine amino-
acid substitutions that have resulted in a stable surrogate for a
heteromeric neurotransmitter site that binds glycine. This
system could be exploited in early-stage drug discovery by use
as a target for the screening of chemical libraries, for structural
elucidation of receptor–ligand interactions, and for biophys-
ical characterization of kinetic and thermodynamic para-
meters relating to ligand binding.
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